Oracle announced a collaboration with Baylor College of Medicine to advance research into alcohol-related liver disease (ALD). Baylor will utilize Oracle Health's AI data platform and its real-world dataset, which contains over 120 million anonymized patient records, to create one of the largest ALD patient cohorts for research. The goal of the partnership is to enable earlier identification of ALD, gain a deeper understanding of how the disease progresses, and help develop more effective prevention and treatment methods. Baylor intends to expand its research cohort to over one million patients using Oracle's technology. The collaboration showcases a specific use case for Oracle's growing capabilities in the health and life sciences sector, applying AI and large-scale data analysis to address significant public health challenges.
Oracle Partners with Baylor College of Medicine to Advance Liver Disease Research Using AI
ORCL
Related News
ORCL
Developers Pressure Oracle to Cede Control of MySQL Amid AI-Era Stagnation Fears
ORCL
Oracle Stock Rises on Hedge Fund Buying and Tech Sector Recovery
ORCL
Oracle stock rises in pre-market trading amid broader tech recovery and upcoming earnings catalyst
ORCL
Oracle Shares Slide 3.9% as AI Debt and Fraud Lawsuits Cloud Growth Outlook
ORCL